about
The evolutionary biology of poxvirusesThe immunology of smallpox vaccines.In vitro analysis of acetalated dextran microparticles as a potent delivery platform for vaccine adjuvants.Genome-wide genetic associations with IFNγ response to smallpox vaccineImpact of ST-246® on ACAM2000™ smallpox vaccine reactogenicity, immunogenicity, and protective efficacy in immunodeficient mice.Long term recall of memory CD8 T cells in mice to first and third generation smallpox vaccines.Safety and immunogenicity of LC16m8, an attenuated smallpox vaccine in vaccinia-naive adults.Susceptibility to vaccinia virus infection and spread in mice is determined by age at infection, allergen sensitization and mast cell statusA Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA Smallpox Vaccine (IMVAMUNE) in 18-40 Year Old Subjects with Diagnosed Atopic Dermatitis.A Randomized, Double-Blind, Placebo-Controlled Phase II Trial Investigating the Safety and Immunogenicity of Modified Vaccinia Ankara Smallpox Vaccine (MVA-BN®) in 56-80-Year-Old Subjects.Attenuation of Vaccinia VirusRepeated high-dose (5 × 10(8) TCID50) toxicity study of a third generation smallpox vaccine (IMVAMUNE) in New Zealand white rabbitsSmallpox vaccines for biodefense.Molecular smallpox vaccine delivered by alphavirus replicons elicits protective immunity in mice and non-human primates.Viral serine/threonine protein kinasesAnti-Infectious Human Vaccination in Historical Perspective.Immunogenicity and safety of three consecutive production lots of the non replicating smallpox vaccine MVA: A randomised, double blind, placebo controlled phase III trial.The US Military Commitment to Vaccine Development: A Century of Successes and Challenges.
P2860
Q24652228-E0AC1222-FDA0-48D2-BC05-0235B594210DQ33679943-AA365E73-83A7-4453-9500-0FA7C9CFB7A7Q33901007-A45BF28C-7FC2-4D6C-A3A9-BEE19E73BBC5Q34221936-244D6EED-9C10-4396-86B1-957E6991074AQ34502253-AA47AD36-4E50-491E-A50A-B1F3703A31F0Q34556632-CBACEAC5-F067-46FA-987A-3FBA1F5D3137Q35557123-22CA4119-0504-4BED-AC68-D73B8AE64DBEQ35795457-DAD1A8F9-CC03-44D8-BED5-3E06D27F7D46Q35800226-0CAE5147-9CC4-446F-8C8E-73D51C511B12Q36057928-0A5DCFEB-E294-44EB-A634-6423CBB32CDAQ36475175-4FFA65C4-CAB6-4973-90BE-C083E934770DQ37135398-754B214C-8D26-4C90-8408-E3FC0B3C807EQ37393765-78D00805-4E2A-4EB8-AE3D-C053BB747458Q37461110-ACB41CC8-6476-4507-BFBD-F1A06B29DAA1Q37810382-6AE4CA7F-74A7-4439-9745-84977E7B46D0Q40129444-6F517037-26BB-4ABA-BC3C-C95F0DF856E2Q55329093-7DE05C52-50D9-4439-8613-380EDF21190FQ55432397-ECCB01F0-39E3-4234-A17B-8FCA0F7AC4EE
P2860
description
2008 nî lūn-bûn
@nan
2008 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
name
Smallpox vaccines for biodefense: need and feasibility
@ast
Smallpox vaccines for biodefense: need and feasibility
@en
Smallpox vaccines for biodefense: need and feasibility
@en-gb
Smallpox vaccines for biodefense: need and feasibility
@nl
type
label
Smallpox vaccines for biodefense: need and feasibility
@ast
Smallpox vaccines for biodefense: need and feasibility
@en
Smallpox vaccines for biodefense: need and feasibility
@en-gb
Smallpox vaccines for biodefense: need and feasibility
@nl
prefLabel
Smallpox vaccines for biodefense: need and feasibility
@ast
Smallpox vaccines for biodefense: need and feasibility
@en
Smallpox vaccines for biodefense: need and feasibility
@en-gb
Smallpox vaccines for biodefense: need and feasibility
@nl
P2860
P3181
P1476
Smallpox vaccines for biodefense: need and feasibility
@en
P2093
Andrew W Artenstein
John D Grabenstein
P2860
P304
P3181
P356
10.1586/14760584.7.8.1225
P407
P577
2008-10-01T00:00:00Z